Turkish Journal of Medical Sciences
Volume 48

Number 2

Article 22

1-1-2018

Increased micronucleus count predicts malignant behavior in
pleural effusion fluid
TUBA DİLAY KÖKENEK ÜNAL
İPEK ÇOBAN

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
ÜNAL, TUBA DİLAY KÖKENEK and ÇOBAN, İPEK (2018) "Increased micronucleus count predicts
malignant behavior in pleural effusion fluid," Turkish Journal of Medical Sciences: Vol. 48: No. 2, Article
22. https://doi.org/10.3906/sag-1711-63
Available at: https://journals.tubitak.gov.tr/medical/vol48/iss2/22

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Medical Sciences

Turk J Med Sci
(2018) 48: 354-360
© TÜBİTAK
doi:10.3906/sag-1711-63

http://journals.tubitak.gov.tr/medical/

Research Article

Increased micronucleus count predicts malignant behavior in pleural effusion fluid
1,

1

2

Tuba Dilay KÖKENEK ÜNAL *, İpek ÇOBAN
Department of Pathology, Faculty of Health Sciences, Kayseri Research and Training Hospital, Kayseri, Turkey
2
Department of Pathology, Gayrettepe Florence Nightingale Hospital, İstanbul, Turkey
Received: 10.11.2017

Accepted/Published Online: 01.02.2018

Final Version: 30.04.2018

Background/aim: Micronucleus (MN) frequency is used as a biomarker of chromosomal damage, genome instability, and cancer risk.
The aim of this study was to evaluate the diagnostic usefulness of MN frequency to differentiate between malignant and benign pleural
effusion samples.
Materials and methods: Retrospectively, 78 pleural fluid cytology samples (including 20 cases of benign reactive mesothelial cells, 22
cases of suspicious cytology, and 36 cases of malignant cytology) were examined. The number of micronucleated cells in 1000 wellpreserved cells was counted. Statistical tests were performed to compare the study groups. Recover operating characteristics (ROC)
curve analysis was performed to suggest a cut-off value for predicting malignant behavior.
Results: We evaluated a total of 78 cases of pleural effusion cytology. The number of micronucleated cells was significantly higher in
cases with malignant outcome compared to cases with benign outcome. We observed that malignant samples had more micronucleated
cells than suspicious ones, and suspicious cases had more micronucleated cells than reactive ones. There was a significant difference
among all study groups. In addition, the frequency of MN-containing cells in suspicious cases correlates well with their outcomes.
Conclusion: The results of this study reveal that there is an absolute, consistent, and proportional relationship between MN counts
and malignancy in cytological samples of pleural effusions. MN scoring may be a helpful diagnostic tool for distinguishing malignant
effusions from benign ones, and may be used as an adjunct tool to predict malignant behavior in challenging cases.
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1. Introduction
Micronucleus (MN) is a small extranuclear body found
in the cytoplasm formed during cell division by various
mechanisms (1,2). MN formation can be observed in
healthy individuals due to several causes such as radiation,
drugs, chemicals, chemo- or radiotherapy, chronic
inflammation, and metabolic, infectious, or genetic
diseases (3). Besides these, it may be a way for tumor cells to
survive in inconvenient circumstances by overcoming the
destabilization of chromosomes in the DNA amplification
process (4). MN formation is an indicator of chromosomal
breakage and instability, and can be easily identified by
light microscopy (5). The predictive value of MN formation
in carcinogenesis has been investigated by several studies,
which have indicated that the presence and frequency of
MN can be used as a biomarker of genome instability,
chromosomal damage, and cancer risk (2,6,7).
Evaluation of pleural effusion cytology and pleural
biopsy specimens are among the most controversial topics
in histopathology. Differentiation between malignant and
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reactive mesothelial cells remains challenging not only
in cytological samples, but also in pleural biopsies, even
among expert pathologists (8,9). Invasion remains the
best marker of malignancy for biopsies (10). Recently,
depending on the molecular basis, detection of deletion of
p16 by fluorescence in situ hybridization and loss of BAP1
by immunohistochemistry emerged as two important
reliable markers for discriminating malignant from benign
mesothelial proliferation, both in cytological specimens
and biopsies (11). These are highly specific markers, yet
their sensitivity is much lower (11,12). Despite the welldocumented cytological characteristics of malignant
mesothelioma, several ancillary techniques, and newly
described molecular markers (13), differential diagnosis
can be challenging in routine practice. On the other hand,
the immunohistochemical staining panel, recommended by
the International Mesothelioma Interest Group and World
Health Organization, is used to distinguish metastatic
carcinoma from mesothelial proliferation, in addition to
well-described morphological features (10,14–16).
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In the present study, we evaluated the presence and
frequency of MN count in conventionally prepared
pleural effusion smears. We hypothesized that this
chromosomal instability marker, which is easily detectable
by light microscopy, can help us in differential diagnosis.
Furthermore, it may be used as an adjunct tool for
separating malignant from benign cells of pleural effusions.
To the best of our knowledge, this is the first study in the
literature that reveals MN scoring in pleural effusions,
including in suspicious cases.
2. Materials and methods
This cross-sectional study was conducted following
institutional review board approval (ID: 20102016/5721). The cases with pleural effusions were retrospectively
selected among surgical pathology reports, signed out
between 2011 and 2016 from the archives of the Pathology
Department, Kayseri Training and Research Hospital.
Cases with malignant and suspicious cytological diagnosis
and histopathological correlation were included in the
study. Stained slides were deidentified and reviewed by
two pathologists. Cases with only uniform agreement on
both sample types were included in the study. Hypocellular
samples and slides full of degenerated cells or staining
artifacts were exempt. Finally, a total of 78 cytological
cases were included. Specifically, 36 cases of malignant
cytology ((16 cases of malignant mesothelioma (MM), 20
cases of adenocarcinoma (AC) originating from lung (10),
breast (6) and over (4)), 22 cases of suspicious cytology,
and 20 cases of reactive mesothelial cells were selected and
reviewed for this study.
Cytological evaluation was performed according to the
established morphological criteria and findings of routine
immunohistochemical staining. Cases were classified
into three main groups as benign reactive mesothelial
proliferation (n = 20), suspicious for malignancy (n =
22), and malignant (n = 36) ((further subdivided into two
groups as AC (n = 20) and MM (n = 16)). All patients
with reactive mesothelial cells had neither history of
malignancy nor any suspected laboratory or radiological
findings at the time of diagnosis, as well as an average
of 2 years follow-up. In suspicious cases, occasional
mild to moderate cytological and structural atypia was
observed, and the epithelial origin of cells was excluded
by immunohistochemical methods. However, MM could
not be excluded. By succeeding pleural biopsies, 12 cases
of suspicious cytology were diagnosed as MM and 10
cases of suspicious cytology were diagnosed as reactive
proliferation.
Alcohol-fixed and air-dried smears as well as cell blocks
were prepared from pleural effusions and were evaluated.
Conventionally prepared and May–Grünwald–Giemsa
(MGG) stained slides were used for MN counting.

2.1. Evaluation and quantification of MN
Each cytology slide was reviewed under 400× and/or 600×
magnification. Well-preserved mesothelial cells in benign
cases and tumor cells in malignant cases were investigated
for the presence and frequency of MN. The number of
micronucleus-containing cells was counted per 1000 cells.
In the review process, scoring of MN took approximately
25 min per case.
For the evaluation of MN, we used the following preestablished criteria: a diameter smaller than 1/3 of the
main nucleus, round/oval shape with regular contours,
same staining intensity with the main nucleus, and no
connection to the main nucleus (3,17) (Figure).
We avoided degenerated cells and did not evaluate cells
without cytoplasm. Additionally, with careful observation,
we eliminated possible mimickers such as apoptotic
fragments, superimposed lymphocytes, and staining
artifacts, as mentioned in the literature (3).
2.2. Statistical analysis
Statistical analyses were performed using IBM SPSS 22.0.
Numerical variables were calculated by medians (min–max)
and means with SDs for different diagnostic groups. The
Kolmogorov–Smirnov test was used to examine whether
the numerical variables showed normal distribution or
not. The Levene test was used to assess the equality of
variances. The Mann–Whitney U test was performed to
compare the number of cells with MN between benign and
malignant groups, and the Kruskal–Wallis test was used
for the comparison among groups. The Siegel Castellan
test was performed for pairwise comparison of different
groups. The post hoc power test was performed to test
whether it has adequate power or not. Recover operating
characteristics (ROC) curve analysis was used to detect the
best cut-off values to indicate malignancy with the highest
sensitivity and specificity sum. Positive and negative
predictive values were calculated. P < 0.01 was regarded as
statistically significant.
3. Results
From the total series of 78 cases, 48 cases had a malignant
outcome and 30 cases had a benign outcome. Malignant
cases included both malignant mesothelioma (n = 28)
and adenocarcinoma (n = 20). Twelve cases of MM were
cytologically diagnosed as suspicious. The age of the
patients ranged from 22 to 92. There were 44 male and 34
female patients.
When we compared our groups, we found that the
MN score was significantly higher in malignant cases than
in benign ones; the mean value of the MN count was 24
in malignant samples and only 6 in benign samples (P
< 0.001, with a power of 0.99, Table 1). A comparison
between cases with reactive mesothelial cells and cases
with suspicious mesothelial proliferation revealed a
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Figure. Presence of micronucleus (a) in a reactive mesothelial
cell, (b) in a suspicious mesothelial cell, (c) in adenocarcinoma
cells, (d) in a malignant mesothelioma cell (MGG, 40×).
Table 1. MN-containing cells in pleural fluid cytology of malignant and benign cases.

Number of
MN-containing cells

Cases with benign
outcome (n = 30)

Cases with malignant
outcome (n = 48)

P

6.4 ± 2.6
6 [1–10]

24.8 ± 10.3
24 [11–60]

<0.001*

MN: micronucleus, *: significant.

significant difference in MN count. Furthermore, our
study showed that there is a significant difference between
suspicious and malignant cases (P < 0.001, Table 2). In
suspicious cytological samples, we observed that the cases
with a malignant outcome had more micronucleated cells
compared to cases with a benign outcome. The difference
was statistically significant (P < 0.001, with a power of
0.99, Table 3). On the other hand, we observed that AC
cases had a slightly higher number of micronucleated cells
than MM cases. However, when we compared MM to AC
cases, the number of MN-containing cells did not differ
significantly (P = 0.172, Table 4).
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Moreover, by using a ROC curve analysis, we revealed
a cut-off of 11 for the MN count, giving a sensitivity of
1.0 and a specificity of 1.0 for detecting malignant cases
(AUC = 1.0). While all the malignant outcome cases had ≥
11 MN count, the highest MN count in only one-benignoutcome cases was 10.
The statistical analysis did not exhibit any relation
between MN scores, age, and sex.
4. Discussion
In this retrospective cross-sectional study, we found that
malignant and suspicious cytological samples have a higher
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Table 2. Frequency of micronucleated cells in benign, suspicious, and malignant cytological
samples.

Number of
MN-containing cells

Benign
(n = 20)

Suspicious
(n = 22)

Malignant
(n = 36)

P

5.8 ± 2.9
5 [1–10]

16.3 ± 8
16 [6–28]

25.2 ± 11.5
25 [11–60]

<0.001*

MN: micronucleus, *: significant.
Table 3. Micronucleus frequency in suspicious cytological samples with different
outcomes.
Suspicious cytology (n = 22)

Number of MN
containing cells

With benign
outcome (n = 10)

With malignant
outcome (n = 12)

P

8.2 ± 2.3
8 [6–12]

23.2 ± 5.2
24 [16–28]

<0.001*

MN: micronucleus, *: significant.
Table 4. MN counts in cytological slides in cases with a malignant outcome.
Histopathological diagnosis
MM

AC

P

Total

Number of MN; mean ± SD; median [min–max]

Cytological
diagnosis

Suspicious cytology with
malignant outcome

n = 12
23.2 ± 5.2
24 [16–28]

n=0

Malignant cytology

n = 16
21.7 ± 5.0
21[14–28]

n = 20
29.0 ± 14.1
25 [11–60]

Total

28

20

12
0.172
36
48

MN: micronucleus; MM: malignant mesothelioma; AC: adenocarcinoma.

MN score than benign pleural effusion samples consisting
of reactive mesothelial proliferation. We noted that
malignant cases had a higher MN count than suspicious
cases, and suspicious cases had a higher MN count than
benign cases. The difference among all study groups was
significant (P < 0.001). In addition, micronucleus scoring
in suspicious cases correlates well with their outcome. We
concluded that MN scoring is a simple and easy-to-use
method for the evaluation of pleural effusions, especially
in challenging cases. It can be used as an adjunct tool,
because an increased number of cells containing MN have

a good diagnostic ability to discriminate between benign
and malignant cases.
MN is a small round/oval nucleus not connected
to the main nucleus. It contains whole chromosome or
chromosomal fragment (17,18). Potential mechanisms
that lead to MN formation include chromosomal
breakage, dysfunction of mitotic apparatus, and defect
in mitotic spindles (3,19). MN can be formed in healthy
individuals, and the presence of micronucleated cells can
indicate initial stages of nuclear damage for any reason.
Consistently with the literature, but to a lesser extent,
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cases with benign reactive mesothelial cells in our study
showed micronucleus formation. This nuclear feature is
a nuclear envelope alteration indicating chromosomal
instability, and it is included in the list of cytological
criteria of malignancy (20) and high frequency of MN
formation can be a clue for malignancy (21). Accordingly,
in the present study, we counted a considerably high
number of micronucleated cells in malignant cases.
Under the light microscope, MN formation is a clearly
visible, but often overlooked cytological finding. It is not
even mentioned in pathological examination, in contrast
to other nuclear alterations such as moldings, inclusions,
grooves, nuclear shape irregularities, koilocytes, and
chromatin texture [20]. However, it is an important
indicator of genetically damaged cells and is found more
frequently in malignant cells. Surprisingly, there are
limited studies in the literature evaluating its diagnostic
usefulness from a cytopathological point of view. In the
present study, we evaluated the presence and frequency
of MN in pleural fluid cytology. The limited studies in
this field clearly pointed out that neoplastic lesions had
high MN counts compared to their benign counterparts
(22–24). Consistently with the literature, we found that
all the cytological smears with a malignant outcome had
a significantly higher MN count compared to benign
ones (P < 0.001, Table 1). According to the literature,
in the fine needle aspirates of breast lesions, ductal
carcinoma cells had significantly higher MN counts
than cells of fibroadenoma (25,26). Likewise, in cervical
smears, cases of high-grade intraepithelial lesions or
invasive carcinoma had more micronucleated cells than
cases of reactive changes (27). Furthermore, the presence
of MN was noted in malignant thyroid aspirates (28,29).
It is found that the smears of papillary thyroid carcinoma
include a significantly higher number of micronucleated
cells than smears of follicular nodular disease (29).
Besides fine needle aspiration smears, the frequency
of MN helped to detect atypical cells in urine samples
and ascitic effusion, indicating malignancy (24,30,31).
Moreover, our findings are consistent with the findings
of studies on the frequency of MN in exfoliative, fine
needle aspiration, and effusion smears (22,25–29,30–34).
Pleural effusion cytology is the first important step
in the diagnosis of malignancy, especially malignant
mesothelioma. Although cases with prominent benign
or malignant morphology are far from a diagnostic
challenge, suspicious cases are often problematic. There
is no definite method for differential diagnosis (10). The
most important part of this study was exploring the
role of MN scoring in suspicious cases. We observed
that suspicious cases had significantly higher MN
frequency than reactive cases and lower MN frequency
than malignant cases (P < 0.001). These findings are
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compatible with the results of other studies, which
indicate that MN scoring is correlated to the grade of
malignancy in breast aspirations and cervical smears
(22,27,32). In addition, we found that MN counts in these
suspicious cytological samples are correlated well with
their final diagnoses (P < 0.001, with a power of 0.99).
As a limitation to this study, we had a limited number
of suspicious cases, but our results showed clearly that
malignant cells have invariably increased MN frequency,
and MN scoring was completely successful in indicating
malignancy.
Accepting that in daily practice MN counting in
every case might be time-consuming, we consider that
it might be used in challenging cases. A high MN count
can guide pathologists in deciding whether mesothelial
proliferation consists of benign or malignant cells or not,
in addition to other findings.
Moreover, in this study we investigated the role
of MN scoring in differentiating MM from AC. We
found higher MN counts in cases of AC than in MM,
and ROC analysis revealed a cut-off value of 29 for MN
count to distinguish these cases. However, there was no
statistically significant difference between AC and MM.
In this study, we examined a limited number of cases,
which might result from low sample size. We hope that
further extended studies may clarify this point.
Finally, when considering all malignant-outcome
and benign-outcome cases, we suggest a working cutoff value of ≥11 for an MN count with 100% sensitivity
and specificity for detecting malignant cases. A recently
published study found a cut-off value of >5 for malignant
cases; however, it examined fewer cases than ours and
did not evaluate any suspicious ones (35). These studies
are initial and limited, and we think that further and
larger studies are required to attain an absolute cut-off
value for MN scoring.
In conclusion, this is the first study in the literature
that indicates the importance of the frequency of MNcontaining cells in suspicious cytological preparations
of pleural effusion, which predicts malignant behavior
in these samples. Based on previous literature and
the promising results of our study, it is clear that
there is an absolute, consistent, and proportional
relationship between MN counts and malignancy in
cytological samples of pleural effusions. This finding is
very important, because discrimination of malignant
mesothelial cells from benign reactive cells may be
difficult, or even impossible, in cytological differential
diagnosis. Therefore, we aimed to reveal the potential
diagnostic usefulness of MN in pleural effusion samples.
The question of usability of this nuclear feature in the
routine cytological examination of pleural specimens
needs to be addressed via further studies.
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